全部资讯｜CELL INTELLIGENCE

Efficacy, safety and cost-effectiveness of CAR-T therapy.

PubMed 2026/02/18 发表Br J Clin PharmacolQ2 · IF 3（JCR 2025）

Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors.

PubMed 2025/10/10 发表J Immunother CancerQ1 · IF 11.7（JCR 2025）

这些结果支持 CLDN6 作为一种癌胎细胞表面抗原，可能适合作为儿童实体瘤（包括 CNS 肿瘤）的 CAR-T 细胞靶点。

Role of companion dogs in cancer immunotherapy development.

PubMed 2025/10/01 发表J ImmunolQ2 · IF 4（JCR 2025）

A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.

PubMed 2025/03/01 发表Cancer Res CommunQ2 · IF 4（JCR 2025）

IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.

PubMed 2024/11/20 发表J Immunother CancerQ1 · IF 11.7（JCR 2025）

我们的研究确定，细胞外基质蛋白 TNC 的 C 结构域是治疗儿童实体瘤和脑肿瘤的一种有前景的 CAR-T 细胞疗法。

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.

PubMed 2023/10/01 发表Acta BiomaterQ1 · IF 10.4（JCR 2025）

Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions.

PubMed 2023/02/21 发表bioRxiv

Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.

PubMed 2022/10/03 发表Int Rev ImmunolQ2 · IF 5.4（JCR 2025）

Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing

PubMed 2022/08/02 发表Mol Cancer TherQ1 · IF 6.9（JCR 2025）

全部资讯 9